JPWO2022043483A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022043483A5
JPWO2022043483A5 JP2023513414A JP2023513414A JPWO2022043483A5 JP WO2022043483 A5 JPWO2022043483 A5 JP WO2022043483A5 JP 2023513414 A JP2023513414 A JP 2023513414A JP 2023513414 A JP2023513414 A JP 2023513414A JP WO2022043483 A5 JPWO2022043483 A5 JP WO2022043483A5
Authority
JP
Japan
Prior art keywords
sequence
cell
seq
antigen
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539596A (ja
JP2023539596A5 (https=
Publication date
Priority claimed from GBGB2013477.1A external-priority patent/GB202013477D0/en
Application filed filed Critical
Publication of JP2023539596A publication Critical patent/JP2023539596A/ja
Publication of JPWO2022043483A5 publication Critical patent/JPWO2022043483A5/ja
Publication of JP2023539596A5 publication Critical patent/JP2023539596A5/ja
Pending legal-status Critical Current

Links

JP2023513414A 2020-08-27 2021-08-27 細胞においてポリペプチドを発現させるための核酸構築物 Pending JP2023539596A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2013477.1A GB202013477D0 (en) 2020-08-27 2020-08-27 Nucleic acid constructs for expressing polypeptides in cells
GB2013477.1 2020-08-27
PCT/EP2021/073714 WO2022043483A1 (en) 2020-08-27 2021-08-27 Nucleic acid constructs for expressing polypeptides in cells

Publications (3)

Publication Number Publication Date
JP2023539596A JP2023539596A (ja) 2023-09-15
JPWO2022043483A5 true JPWO2022043483A5 (https=) 2024-09-03
JP2023539596A5 JP2023539596A5 (https=) 2024-09-03

Family

ID=72749810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513414A Pending JP2023539596A (ja) 2020-08-27 2021-08-27 細胞においてポリペプチドを発現させるための核酸構築物

Country Status (9)

Country Link
US (1) US20250144137A1 (https=)
EP (1) EP4204438A1 (https=)
JP (1) JP2023539596A (https=)
CN (1) CN116209455A (https=)
AU (1) AU2021335027A1 (https=)
CA (1) CA3190502A1 (https=)
GB (2) GB202013477D0 (https=)
TW (1) TW202227469A (https=)
WO (1) WO2022043483A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
WO2022221669A1 (en) * 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
WO2023180690A1 (en) 2022-03-22 2023-09-28 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
EP4519417A1 (en) * 2022-05-05 2025-03-12 Quell Therapeutics Limited Method for maintaining suppressive activity of regulatory t cells
WO2024196815A1 (en) * 2023-03-21 2024-09-26 The Regents Of The University Of California Method for suppressing immune responses to transplanted cells, tissues and organs
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
WO2005001048A2 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
MX2007014673A (es) 2005-05-24 2008-04-08 Avestha Gengraine Tech Pvt Ltd Metodo para la produccion de un anticuerpo monoclonal para cd20 para el tratamiento de linfoma de celular b.
JP5626164B2 (ja) 2011-07-26 2014-11-19 日本精工株式会社 ステアリングコラム用支持装置
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
SG11201912010XA (en) * 2017-06-12 2020-01-30 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy
EP3697820A4 (en) * 2017-10-17 2022-01-05 The General Hospital Corporation PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
EP3883955A1 (en) * 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
MX2021009357A (es) * 2019-02-04 2021-11-17 Ksq Therapeutics Inc Dianas de genes de combinacion para mejorar la inmunoterapia.

Similar Documents

Publication Publication Date Title
AU2017301880C1 (en) Immunomodulatory polypeptides and related compositions and methods
CA3158025C (en) Anti-bcma chimeric antigen receptors
CN110582509A (zh) 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
EP4458957A2 (en) Optimized lentiviral transfer vectors and uses thereof
EP3283526B1 (en) Chimeric protein
GB2614158A (en) Nucleic acid constructs for expressing polypeptides in cells
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
JP2025122064A (ja) 細胞
HK1243107A1 (en) Chimeric protein
CN120917046A (zh) 新型cd19结合剂、包含所述cd19结合剂的car-t构建体及其使用方法
CN111094349A (zh) 嵌合抗原受体和结合cxcr5的car-t细胞
US20260035662A1 (en) Chimeric antigen receptor
CN116745319A (zh) 前列腺癌嵌合抗原受体
JP2022548468A (ja) Car-cd123ベクター及びその使用
KR20240019811A (ko) Gpc3 결합 분자
KR20250089526A (ko) Il18과 조합된 신규한 cd19 결합제를 포함하는 car-t 작제물 및 이의 사용 방법
JPWO2022043483A5 (https=)
EP4387656A1 (en) Binding domain
JP2023540023A (ja) Ceaを認識するキメラ抗原受容体(car)発現細胞
JP2023540022A (ja) チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにCD44v6を認識するCAR発現細胞
WO2024230793A1 (en) Chimeric antigen receptors and methods of use thereof
US20250312453A1 (en) Antibody targeting ccr8 and its applications
WO2022048621A1 (en) Compositions and methods to target anti-rh antibody
HK40108020A (zh) 抗cd33抗体及其用途
HK40123335A (zh) 包含与il18组合的新型cd19结合剂的car-t构建体及其使用方法